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Abstract
 
Chronic inflammation leading to pulmonary fibrosis develops in response to environmental
pollutants, radiotherapy, or certain cancer chemotherapeutic agents. We speculated that lung
injury might be mediated by p53, a proapoptotic transcription factor widely implicated in the
 
response of cells to DNA damage. Intratracheal administration of bleomycin led to caspase-medi-
ated DNA fragmentation characteristic of apoptosis. The effects of bleomycin were associated
with translocation of p53 from the cytosol to the nucleus only in alveolar macrophages that had
been exposed to the drug in vivo, suggesting that the lung microenvironment regulated p53
 
activation. Experiments with a thiol antioxidant (
 
N
 
-acetylcysteine) in vivo and nitric oxide
(NO) donors in vitro confirmed that reactive oxygen species were required for p53 activation.
A specific role for NO was demonstrated in experiments with inducible nitric oxide synthase
 
(iNOS)
 
2
 
/
 
2
 
 macrophages, which failed to demonstrate nuclear p53 localization after in vivo
bleomycin exposure. Strikingly, rates of bleomycin-induced apoptosis were at least twofold
higher in p53
 
2
 
/
 
2
 
 C57BL/6 mice compared with heterozygous or wild-type littermates. Simi-
larly, levels of apoptosis were also twofold higher in the lungs of iNOS
 
2
 
/
 
2
 
 mice than were ob-
served in wild-type controls. Consistent with a role for apoptosis in chronic lung injury, levels
of bleomycin-induced inflammation were substantially higher in iNOS
 
2
 
/
 
2
 
 and p53
 
2
 
/
 
2
 
 mice
compared with wild-type controls. Together, our results demonstrate that iNOS and p53 me-
diate a novel apoptosis-suppressing pathway in the lung.
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Introduction
 
Pulmonary toxicity leading to epithelial hyperplasia, in-
flammation, and fibrosis is the unfortunate consequence of
 
exposure of the lung to environmental contaminants, 
 
g
 
 ir-
radiation, and a variety of cancer chemotherapeutic agents
(1, 2). Early administration of corticosteroids can alleviate
(but not prevent) inflammation associated with these re-
sponses, but there is no effective treatment for pulmonary
 
fibrosis, and mortality in these patients is high (
 
z
 
50%
within 5 yr; reference 2). Furthermore, a relationship be-
tween dose and risk of developing lung injury appears to
exist in most cases, but this association is poorly under-
stood, and it is currently impossible to predict which pa-
 
tients will develop lung disease. Risk factors include age,
simultaneous or prior therapy with other agents, and hy-
perbaric oxygen therapy (3), but disease onset can occur
many years after exposure for reasons that are still not clear.
Overall, very little is known about the pathophysiological
event(s) underlying the initiation of pulmonary fibrosis.
One feature shared by all of the fibrogenic agents dis-
cussed above is their capacity to induce DNA damage in
target cells. Genotoxic damage initiates a cellular response
involving the tumor suppressor, p53, which acts to inhibit
cell cycle progression and activate DNA repair (4, 5) and/
or to stimulate apoptosis (6). Reactive oxygen species ap-
pear to play a critical role in regulating p53 function (7),
and p53 controls the expression of a large number of redox
regulatory proteins (8). In particular, recent work has
 
Address correspondence to David J. McConkey, Department of Cancer
Biology-173, U.T. M.D. Anderson Cancer Center, 1515 Holcombe
Blvd., Houston, TX 77030. Phone: 713-792-8591; Fax: 713-792-8747;
E-mail: dmcconke@notes.mdacc.tmc.edu 
858
 
p53 Suppresses Apoptosis in the Lung
 
shown that nitric oxide (NO) controls p53 activation, and
that p53 can regulate inducible NO synthase (iNOS)
 
1
 
/
NOS-2 promoter activity (9). Given the unique role of ox-
ygen in the lung microenvironment (10), it is likely that
p53 plays a critical role in the maintenance of normal lung
physiology. The frequent detection of signature inactivat-
ing p53 mutations in lung cancer indicates that disruption
of the pathway contributes to neoplastic transformation
(11, 12).
One of the features of apoptosis that distinguishes the
process from necrosis is the lack of associated inflammation.
However, apoptotic cells in tissues are usually cleared very
rapidly, and the potential consequences of defective clear-
ance are not known. Antibodies to apoptosis-associated an-
tigens (DNA, poly[ADP-ribose] polymerase, phosphati-
dylserine, DNA-dependent protein kinase) are commonly
detected in patients with autoimmune disease (13), and
Savill et al. (14) have speculated that apoptosis plays an im-
portant role in inflammatory injury to the kidney (glomer-
ulonephritis). Given that uptake of apoptotic bodies serves
as one source of antigens for presentation by dendritic cells
(15), it is possible that chronic exposure to apoptotic debris
is involved in inflammatory lung injury. As a first step in
testing this hypothesis, the biological mechanism(s) mediat-
ing apoptosis and cellular targets must be identified. Con-
sidering the evidence outlined above, we speculated that
iNOS and/or p53 might be required for apoptosis induc-
tion and subsequent inflammation. To test this possibility
directly, we analyzed the effects of one widely studied
stimulus for pulmonary fibrosis, the cancer chemothera-
peutic agent bleomycin, on p53 activity and apoptosis in
wild-type, iNOS
 
2
 
/
 
2
 
, and p53
 
2
 
/
 
2
 
 C57BL/6 mice, because
this strain is considered fibrosis prone (16).
 
Materials and Methods
 
Mice.
 
iNOS knockout (iNOS
 
2
 
/
 
2
 
) mice (17) were provided
by Dr. Carl Nathan (Cornell University, New York, NY). Het-
erozygous (p53
 
1
 
/
 
2
 
) C57BL/6 breeding pairs were obtained from
The Jackson Laboratory. Animals were bred and housed in a spe-
cific pathogen-free animal facility of the Department of Cancer
Biology at the University of Texas M.D. Anderson Cancer Cen-
ter. Mice were genotyped by PCR amplification of tail DNA ac-
cording to a protocol that was provided by Dr. Tyler Jacks (Mas-
sachusetts Institute of Technology, Cambridge, MA). Wild-type,
p53
 
1
 
/
 
2
 
, p53
 
2
 
/
 
2
 
, and iNOS
 
2
 
/
 
2
 
 animals were used in subsequent
experiments. Bleomycin (Bristol-Myers Squibb) was resuspended
in 0.9% saline with or without antioxidants or benzyloxycarbo-
nyl-Val-Ala-Asp fluoromethyl ketone (zVADfmk) and was ad-
ministered via intratracheal instillation in a total volume that did
not exceed 50 ml.
 
Isolation of Alveolar Macrophages.
 
C57BL/6 mice were anes-
thetized with 60 mg/kg sodium phenobarbitol, and were exsan-
guinated by severing the dorsal artery. The lungs were removed
 
and lavaged five times with 1.0 ml aliquots of PBS. Cells were re-
covered by centrifugation (1500 rpm for 5 min). Recovered cells
(0.5 
 
3
 
 10
 
6
 
 per mouse) were
 
 
 
.
 
95% macrophages and 
 
.
 
99% via-
ble as determined by trypan blue exclusion. Macrophages were
cultured in MEM medium with 10% fetal bovine serum (GIBCO
BRL).
 
DNA Fragmentation Analysis.
 
Apoptosis was measured by
propidium iodide (PI) staining for determination of the percent-
age of cells with subdiploid DNA content as described previously
(18). Cells were harvested by centrifugation and incubated at 4
 
8
 
C
for 24 h in PBS containing 50 
 
m
 
g/ml PI and 0.1% Triton X-100,
and PI fluorescence was measured by FACS
 
®
 
 (FACScan™; Bec-
ton Dickinson). Alternatively, oligonucleosomal DNA fragmen-
tation (“DNA ladders”) was detected by agarose gel electrophore-
sis. Cells were lysed in a buffer containing 0.5% Triton X-100, 20
mM EDTA, and 50 mM Tris (pH 8.0), and DNA fragments
were harvested by centrifugation for 15 min at 12,000 
 
g
 
 (19). The
DNA in the supernatants was precipitated by addition of 2 vol
isopropanol and NaCl (to 0.5 M final concentration) for 24 h at
 
2
 
20
 
8
 
C after addition of 2 vol isopropanol and NaCl (to 0.5 M
final concentration). After centrifugation at 12,000 
 
g
 
 for 10 min,
precipitates were harvested, dried, and incubated for 1 h in TE
buffer (10mM Tris [pH 8.0] and 1 mM EDTA] containing 0.2
mg/ml proteinase K and 1 mg/ml RNase A. The DNA fragments
were resolved by electrophoresis for 1 h at 70 V on 1.5% agarose
gels preimpregnated with ethidium bromide, and were detected by
UV transillumination and photographed.
 
DNA Nick End Labeling of Tissue Sections.
 
Lung sections were
fixed by inflation with buffered 10% formalin solution and
embedded in paraffin. Thin (4 
 
m
 
m) sections were prepared, and
DNA fragmentation was analyzed by TdT-uridine nick end la-
beling (TUNEL [20]) using a commercial kit (Promega). Tissue
sections were deparaffinized in xylene, rehydrated in alcohol, and
transferred to PBS. Tissues were then fixed in 4% paraformalde-
hyde at room temperature for 5 min. Tissues were incubated
with 20 
 
m
 
g/ml proteinase K for 10 min at room temperature. Af-
ter two 5-min washes with PBS, tissues were preincubated with
TdT buffer for 10 min at room temperature. TdT and buffer
were then added to the tissue sections, and the slides were incu-
bated in a humid atmosphere at 37
 
8
 
C for 1 h. EDTA (10 mM in
water) was added to the tissues for 5 min to stop the reaction.
The slides were washed three times (5 min each) with PBS, and
in some experiments they were stained with
 
 
 
10
 
 
 
m
 
g/ml PI for 10
min before they were washed again three times (5 min each) with
PBS. Cover slips were mounted using Prolong (Molecular
Probes). The slides were analyzed using an Olympus Inverted
System Microscope IX70, and photographs were taken with a
Nikon 35-mm camera.
 
Immunocytochemistry and Confocal Microscopy.
 
Isolated alveolar
macrophages were washed with PBS, fixed with 4% paraformalde-
hyde for 20 min at 4
 
8
 
C, and washed twice in PBS. Macrophages
were mounted by cytospin, permeabilized with 0.2% Triton X-100
for 5 min at 4
 
8
 
C, and washed with PBS. Cells were blocked in a
buffer containing 10% goat serum and 5% normal horse serum
in PBS, incubated overnight at 4
 
8
 
C with a polyclonal sheep anti–
mouse p53 antibody (pan-p53; Boehringer), diluted 1:80 in
blocking buffer. Cells were washed once with PBS containing
0.01% Brij and twice with PBS (5 min each) before incubation
with fluorescein-conjugated rabbit anti–sheep polyclonal second-
ary antibody (Cappel) diluted 1:200 in blocking buffer. Samples
were analyzed using a Zeiss confocal laser scanning microscope
(upright version) equipped with an argon and HeNe laser. Signals
were collected by photomultipliers with a 590-nm (PI) long pass
 
1
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N
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filter and a 520–560-nm (FITC) band pass filter, respectively.
Digitized images were transmitted to a Macintosh-based image
analysis system through a GPIB interface using BDS-LSM soft-
ware (Biological Detection Systems). Composite images were as-
sembled using Adobe Photoshop (Adobe Systems, Inc.).
 
Immunohistochemical Analyses.
 
Formalin-fixed, paraffin-embed-
ded sections (4 
 
m
 
m) were deparaffinized in xylene, rehydrated
in alcohol, and transferred to PBS. Antigen retrieval was per-
formed with target retrieval solution (Dako). Sections were
washed three times with PBS (5 min each) and incubated for 20
min at room temperature with protein blocking solution contain-
ing 5% normal horse serum and 1% normal goat serum. The
blocking solution was removed and the sections were incubated
for 24 h at 4
 
8
 
C with a 1:400 dilution of rabbit polyclonal anti–
mouse iNOS antibody (Transduction Laboratories) or a rabbit an-
tipan cytokeratin antibody (Dako). Tissue sections were washed
once with PBS containing 0.01% Brij and twice with PBS (5 min
each). Sections were then incubated with protein blocking solu-
tion (above) for 10 min at room temperature. The blocking solu-
tion was removed, and the sections were incubated with a 1:400
dilution of FITC-conjugated goat anti–rabbit secondary antibody
(Cappel) for 1 h at room temperature. Sections were washed once
with PBS containing 0.01% Brij and twice with PBS (5 min
each). Cell nuclei were stained with 10 mg/ml PI for 10 min and
washed three times with PBS (5 min each). Cover slips were
mounted using Prolong (Molecular Probes). Immunofluorescence
microscopy was performed using a 40
 
3
 
 objective (ZeissPlan-
Neofluar) on an epifluorescence microscope equipped with nar-
row bandpass excitation filters mounted in a filter wheel (Ludl
Electronic Products) to individually select for green and red fluo-
rescence. Images were captured using a chilled CCD camera
(Hamamatsu) on a PC computer. Images were further processed
using Adobe Photoshop software (Adobe Systems).
 
Laser Scanning Cytometer Analysis.
 
The laser scanning cytom-
eter (LSC; CompuCyte Corporation) is an instrument designed
to enable fluorescence-based quantitative measurements on tissue
Figure 1. Bleomycin induces
apoptosis of alveolar macrophages
in vivo. (A) Cells were exposed to
the indicated doses of bleomycin
for 5 h in vivo, and DNA frag-
mentation was measured by PI
staining and FACS® analysis as
outlined in Materials and Methods.
Results shown are of one experi-
ment typical of three. (B) Bleomy-
cin stimulates oligonucleosomal
DNA fragmentation. Animals
were treated for 5 h in vivo with
vehicle or 50 U/kg bleomycin,
and DNA fragmentation was ana-
lyzed by agarose gel electrophore-
sis. Results are representative of
five experiments. (C) Inhibition of
DNA fragmentation in alveolar macrophages by ZVADfmk. Macrophages were treated with 50 U/Kg
bleomycin in the absence or presence of 10 nmoles (50 ml of a 200-mm stock) zVADfmk, and DNA
fragmentation was quantified by PI or TUNEL staining and FACS® analysis (mean 6 SEM, n 5 4). A
statistically significant difference (P 5 0.034) between bleomycin alone versus bleomycin plus zVAD-
fmk was observed (PI results). TUNEL results are representative of two experiments.
Figure 2. TUNEL analysis of lung tissues
5 h after instillation of 50 U/Kg bleomycin.
Cells were counterstained with PI (total
cells) or an antibody to cytokeratin (epithe-
lial cells). TUNEL-positive cells appear
green and yellow. Top panels, vehicle con-
trols; bottom panels, bleomycin-treated
lungs. Original magnification: 320. 
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sections or other cellular preparations at the single cell level. The
instrument consists of a base unit containing an Olympus BX50
fluorescent microscope and an optics/electronics unit coupled to
argon and HeNe laser support elements and a computer. We
used the instrument to determine the total number of TUNEL-
positive, iNOS-positive, or cytokeratin-positive cells in whole
lung sections. Cell nuclei in lung sections were first contoured by
PI staining (red), and cells positive for iNOS or TUNEL were
subsequently analyzed for emitted green fluorescence. The num-
ber of positive cells and the relative levels of green fluorescence
within each cellular contour were automatically processed by
CompuCyte software to generate a list of properties for that cell.
Results are expressed as total number of cells expressing iNOS,
cytokeratin, or TUNEL per mouse lung section and the mean
level of iNOS expression per cell.
 
Statistical Analysis.
 
All statistical analyses were performed
with SPSS software. Values are presented as mean 
 
6 
 
SEM. Ex-
periments with statistical treatment included an independent sam-
ple 
 
t
 
 test. Differences between values were considered significant
for
 
 P 
 
, 
 
0.05.
 
Results
 
Bleomycin Induces Caspase-dependent DNA Fragmentation in
the Lung.
 
Previous work has shown that bleomycin can
induce direct (double-strand) DNA scission (21). Because
in situ measurements of apoptosis typically rely on the de-
tection of DNA strand breaks, we first analyzed the nature
of bleomycin-induced DNA fragmentation in alveolar
macrophages. Animals were dosed with various concentra-
tions of bleomycin via intratracheal instillation, and apop-
tosis was measured by PI or TUNEL staining and FACS
 
®
 
analysis. Bleomycin-induced DNA fragmentation was dose
dependent (Fig. 1 A) and involved production of typical
oligonucleosome-length DNA fragments, visualized by
agarose gel electrophoresis (Fig. 1 B). Importantly, DNA
fragmentation was significantly blocked by the pancaspase
inhibitor, zVADfmk, whether measured by PI or TUNEL
staining and FACS
 
®
 
 analysis (Fig. 1 C). These data demon-
strate that bleomycin-induced DNA fragmentation is sec-
ondary to apoptosis and is not due to a direct action of the
drug on DNA.
Parallel TUNEL analysis of apoptosis in situ revealed dif-
fuse staining throughout the lung parenchyma (Fig. 2). Im-
munofluorescence two-color analysis of cell death in bron-
chiolar and alveolar epithelial cells by cytokeratin plus
TUNEL staining confirmed that bleomycin stimulated ex-
tensive apoptosis in these cells (Fig. 2). Together, these data
suggest that bleomycin stimulates apoptosis in multiple cell
types within the lung.
 
Bleomycin-induced p53 Activation Is Dependent on Reactive
Oxygen Species in the Lung. 
 
Apoptosis induced by bleo-
mycin and other DNA damaging agents occurs via a p53-
dependent pathway in many model systems (6). Activation
of p53 involves translocation of the protein from the cyto-
plasm to the nucleus (22). We therefore measured this phe-
nomenon as a surrogate for p53 activation in alveolar mac-
rophages exposed to bleomycin in vivo or in vitro. In our
experiments, p53 was visualized with a fluorescein-conju-
gated secondary antibody, and nuclei were detected by
staining with PI. In vehicle-treated cells, p53 was uni-
formly restricted to the cytosol, as demonstrated by non-
overlapping green and red fluorescence (Fig. 3 A). After
exposure to bleomycin in vivo, p53 rapidly translocated to
the nucleus, detected by the appearance of overlapping
green and red fluorescence (yellow) in the cells (Fig. 3 A).
Interestingly, exposure of isolated alveolar macrophages to
bleomycin in vitro had no effect on the subcellular localiza-
tion of p53, which remained entirely cytosolic (Fig. 3 B).
These results strongly suggest that p53 is activated by bleo-
mycin in alveolar macrophages exposed to the drug in
vivo, but not in vitro.
Figure 3. Confocal laser scanning microscopy analysis of p53 localiza-
tion after bleomycin exposure. (A) Effects of in vivo exposure. Animals
were treated for 5 h with 50 U/kg bleomycin, and subcellular p53 local-
ization was determined in isolated alveolar macrophages by immunofluo-
rescence as described in Materials and Methods. p53 was detected with
FITC (green fluorescence); nuclei were visualized by staining for DNA
with PI (red fluorescence). Note that bleomycin exposure caused relocal-
ization of p53 from the cytosol to the nucleus (bottom panels), whereas
p53 remained confined to the cytosol in vehicle-treated controls. (B) Ef-
fects of in vitro exposure. Macrophages were isolated by lavage and
treated with 1.6 U/ml bleomcyin or vehicle (control) for up to 5 h. Cells
were then stained with anti-p53 (green fluorescence) and PI (red fluores-
cence). Note that p53 is confined to the cytoplasm in both the control
and bleomycin-treated cells. Images are representative of a field captured
by microscopy, and results are representative of three experiments. Origi-
nal magnification: 363. 
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The p53 localization results indicated that factor(s)
present within the lung microenvironment play a critical
role in promoting bleomycin-induced p53 activation. Ox-
ygen radicals and oxidative stress are known to exert strong
effects on both lung physiology and p53 function. To ad-
dress the involvement of reactive oxygen species in p53 ac-
tivation, we exposed mice to bleomycin in the absence or
presence of the thiol antioxidant, 
 
N
 
-acetylcysteine (NAC)
in vivo, isolated the macrophages by lavage, and monitored
p53 localization by immunofluorescence confocal mi-
croscopy. NAC (200 nmoles) completely suppressed bleo-
mycin-induced translocation of p53 to the nucleus (Fig. 4
A; compare middle and right panels). Furthermore, NAC
enhanced bleomycin-induced DNA fragmentation three-
fold in alveolar macrophages, as measured by PI staining
and FACS
 
®
 
 analysis (Fig. 4 B). Other antioxidants (
 
a
 
-
tocopherol, ascorbate) also potentiated apoptosis (data not
shown).
We next attempted to reconstitute nuclear translocation
by exposing alveolar macrophages to various oxidants in
vitro. Incubation with the NO donor, 
 
s
 
-nitrosoamino-
pereillamine (SNAP [10 mM]), had no effect on nuclear p53
localization on its own (Fig. 5). However, incubation with
SNAP plus bleomycin (1.6 U/ml) led to strong nuclear
translocation of p53 (Fig. 5). Together, these data strongly
suggest that reactive oxygen species, and in particular NO,
 
are required for bleomycin-induced p53 activation in lung
cells.
 
Increased Bleomycin-induced Apoptosis in p53
 
2
 
/
 
2
 
 Animals.
 
Gene-deficient (p53
 
2
 
/
 
2
 
) mice have been used in previ-
ous studies to establish an unambiguous cause–effect re-
lationship between p53 expression and apoptosis (23,
24). Therefore, we measured bleomycin-induced apopto-
sis in alveolar macrophages from wild-type or p53
 
2
 
/
 
2
 
 mice
to directly determine p53’s involvement in the response.
No differences in the kinetics or magnitude of apoptosis
were observed in the cells incubated with bleomycin in
vitro (Fig. 6 A). Strikingly, however, intratracheal instilla-
tion of bleomycin led to significantly enhanced (twofold
higher;
 
 P 
 
, 
 
0.05) levels of apoptosis in p53
 
2
 
/
 
2
 
 macro-
phages compared with wild-type controls (Fig. 6 B). In addi-
tion, analysis of DNA fragmentation in whole lung tissue
by TUNEL confirmed that more apoptotic cells were
present in the lungs of the p53-deficient animals (Fig. 6
C). To quantify the levels of DNA fragmentation ob-
served, we employed LSC. The LSC is an instrument in
which tissue sections that are mounted on a solid surface
(i.e., a glass microscope slide) are interrogated by a 5-
 
m
 
m
diameter argon laser that repeatedly scans along a line as
the surface is moved past it on a computer-controlled mo-
torized stage. TUNEL and/or immunostained cell prepa-
rations are then contoured by light scatter or counterstain-
Figure 4. (A) Effects of NAC on bleomycin-induced relocalization of
p53 in vivo. Animals were exposed to 50 U/kg bleomycin with or with-
out 200 nmoles NAC, and subcellular p53 localization was analyzed by
immunofluorescence confocal microscopy as outlined in Materials and
Methods. Note that NAC completely inhibited relocalization of p53
from the cytosol to the nucleus. Results are representative of three exper-
iments. Original magnification: 363. (B) Effects of NAC on bleomycin-
induced apoptosis. Animals were exposed to bleomycin with or without
NAC, and DNA fragmentation was quantified by PI staining and FACS®
analysis as described in Materials and Methods (mean 6 SEM, n 5 3). A
statistically significant difference (P 5 0.0002) between bleomycin and
bleomycin plus NAC was observed.862 p53 Suppresses Apoptosis in the Lung
ing with a specific fluorescent dye, and fluorescence
emissions within the contours are automatically processed
by the software to generate a list of properties for the cells
within that tissue. Thus, the LSC can be used very much
like FACS® to obtain two- and three-color fluorescence
intensity information from a heterogeneous tissue speci-
men. LSC-guided contour analysis demonstrated homoge-
neous distribution of apoptotic cells throughout all lobes
of the lung (Fig. 6 D), and direct quantification of
TUNEL-positive cells in whole lung sections confirmed
that rates of apoptosis were about twofold higher in the
p532/2 lungs compared with controls (Fig. 6 E). Further-
more, analysis of epithelial cell apoptosis suggested that
levels of cell death were also elevated in this subpopulation
in the p532/2 mice (Fig. 6 F). Levels of bleomycin-induced
apoptosis were indistinguishable in wild-type and p531/2
cells (data not shown), indicating that a gene dosage effect
is not involved.
p53 Activation Is Dependent on iNOS. Our preliminary
results (Fig. 5) and published reports in the literature (9, 25,
26) suggested that NO can promote p53 activation. We
therefore analyzed bleomycin-induced nuclear p53 local-
ization in alveolar macrophages from wild-type and
iNOS2/2 mice. Intratracheal bleomycin instillation led to
strong p53 activation in wild-type cells, but this effect was
completely absent in cells from the NOS-22/2 animals
(Fig. 7 A). Furthermore, DNA fragmentation was consid-
erably elevated in the NOS-22/2 lungs as determined by
TUNEL staining (Fig. 7 B). LSC contour mapping con-
firmed diffuse apoptosis throughout the lung (Fig. 7 C),
and LSC-mediated quantification of cell death confirmed
that the levels of TUNEL-positive cells were about two-
fold higher in the NOS-22/2 lungs compared with controls
(Fig. 7 D). In subsequent experiments, we analyzed the ef-
fects of bleomycin on iNOS expression in wild-type mice.
Bleomycin induced an increase in iNOS-positive cells
within 5 h (Fig. 8 A), and LSC analysis revealed an approx-
imately twofold increase in the number of positive cells
(Fig. 8 B). However, analysis of fluorescence intensity
demonstrated that the level of iNOS expression was similar
in untreated and bleomycin-treated cells (Fig. 8 C).
Our overall hypothesis is that impaired clearance of apop-
totic debris serves as a trigger for inflammation in the early
stages of lung injury. This hypothesis predicts that levels of
inflammation would be substantially higher in the iNOS2/2
and p532/2 mice compared with wild-type controls be-
cause of increased cell death. Consistent with this idea,
chronic exposure to bleomycin led to marked increases in
inflammatory infiltrate and disruption of alveolar architec-
ture in the iNOS2/2 and p532/2 mice compared with
wild-type littermates (Fig. 9). Increased inflammation was
obvious by 7 d after exposure and persisted up to 14 d, at
which point the iNOS2/2 and p532/2 mice died with high
frequency (Fig. 9, and data not shown). These data strongly
support roles for iNOS and p53 in suppressing inflamma-
tion in this model system.
Figure 5. An NO donor promotes bleo-
mycin-induced p53 activation in vitro. Al-
veolar macrophages were isolated from
wild-type mice by lavage. Cells were
treated with vehicle (control), SNAP (10
mM), bleomycin (1.6 U/ml), or bleomycin
plus SNAP, and p53 localization was ana-
lyzed at 5 min as described in Materials and
Methods. Note that bleomycin plus SNAP
induced relocalization of p53 from the cyto-
plasm to the nucleus, whereas bleomycin or
SNAP did not.863 Davis et al.
Figure 6. Comparison of bleomycin-induced apoptosis in wild-type and p532/2 cells. (A) Effects of bleomycin on alveolar macrophages in vitro. Cells
isolated from wild-type or p53-deficient C57BL/6 littermates were treated with 0.32 U/ml or 1.6 U/ml bleomycin for 5 h, and DNA fragmentation was
measured by PI staining and FACS® analysis (mean 6 SEM, n 5 3). (B) Effects of bleomycin on alveolar macrophages in vivo. Wild-type and p532/2
mice were exposed to 50 U/kg bleomycin for 5 h in vivo, and DNA fragmentation in isolated alveolar macrophages was measured by PI staining and
FACS® analysis (mean 6 SEM, n 5 3). A statistically significant difference (P , 0.05) between the responses measured in cells from p531/1 and p532/2
mice was observed. (C) TUNEL analysis of bleomycin-induced apoptosis in situ. Animals were exposed to vehicle or 50 U/kg bleomycin for 5 h, and
apoptosis was analyzed by TUNEL staining as described in Materials and Methods. Original magnification: 320. (D) Localization of apoptotic cells in
situ. TUNEL-stained slides from untreated or bleomycin-treated lungs were analyzed for distribution of apoptotic cells by LSC. Results are representa-
tive of three independent experiments. (E) Quantification of apoptosis in situ. Apoptotic cells were counted in whole lung sections by LSC. Results are
expressed as mean values 6 SEM from sections obtained from three independent animals. A statistically significant difference (P , 0.05) between p531/1 and
p532/2 lungs was observed. (F) Quantification of epithelial cell apoptosis in situ. Epithelial cell apoptosis was measured by two-color TUNEL plus cyto-
keratin staining as outlined in Materials and Methods. Results are from two separate experiments.864 p53 Suppresses Apoptosis in the Lung
Figure 7. (continues on facing page).865 Davis et al.
Discussion
The p53 tumor suppressor protein plays a central role in
the cellular response to DNA damage, mediating a cell cy-
cle checkpoint that leads to growth arrest or apoptosis. Re-
cent work has demonstrated that apoptosis is one of the
earliest pulmonary alterations detected in mice exposed to
fibrogenic stimuli (27), and it has been suggested that cell
death can directly contribute to inflammation in other tis-
sue model systems (i.e., the kidney; reference 14). Given
that most (if not all) of the known stimuli for pulmonary fi-
brosis induce DNA damage, we speculated that p53 would
participate in the effects of bleomycin. To begin to address
this possibility, we analyzed the effects of bleomycin on
p53 activation and apoptosis in alveolar macrophages and
other lung cell types in wild-type and p532/2 C57BL/6
mice. As expected, exposure of macrophages to bleomycin
in vivo led to rapid translocation of p53 from the cytoplasm
to the nucleus, consistent with p53 activation. Interest-
ingly, parallel immunoblotting experiments demonstrated
that p53 levels did not rise substantially (data not shown),
suggesting that posttranslational mechanisms (i.e., phosphor-
ylation; reference 28) are probably involved.
Almost all published reports on the involvement of p53
in apoptosis have focused on its ability to promote cell
death in response to DNA damage (23, 24, 29, 30). For this
reason, we expected that bleomycin-induced apoptosis
would be attenuated or absent in cells derived from p532/2
mice. Unexpectedly, however, levels of apoptosis were sig-
nificantly elevated in the p532/2 mice compared with
wild-type controls. To our knowledge, ours is the first de-
scription of a p53-dependent survival pathway in the lung.
Although unanticipated, previous work has shown that the
role of p53 in DNA damage–induced apoptosis is tissue and
cell type dependent (31), and p53-dependent inhibition of
apoptosis has even been documented previously in another
model system (32). Our explanation for this apparent para-
dox is that in our system, activation of p53 results in trans-
activation of prosurvival genes, whereas in thymocytes and
certain other tissues, p53 induces the expression of proapop-
totic genes (Bax, Fas). More specifically, it is possible that
the p53 target, p21/WAF1, plays an important role in pro-
moting cell survival in response to exposure to DNA dam-
aging agents in the lung. Recent studies have shown that
p21 inhibits apoptosis in monocytes and other cell types by
a mechanism that may involve inhibition of stress-activated
protein kinase(s) (33, 34). Levels of p53 and p21 are in-
creased in lung tissue from patients with idiopathic pulmo-
nary fibrosis (35), suggesting that the stress response path-
way is activated in the disease. Accumulation of apoptotic
debris in the p532/2 mice may also be linked to reduced
expression of thrombospondin, a p53-regulated gene (36)
that is required for some pathways of apoptotic cell clear-
ance by phagocytic cells (37). Interestingly, thrombospon-
din-12/2 mice exhibit pathological changes within the lung
consistent with inflammation (38), suggesting that impaired
clearance may exacerbate inflammation. We speculate that
p21, thrombospondin, and possibly other targets of p53
play important roles in protecting the lung from inflamma-
tion. Importantly, the C57BL/6 mouse strain used in our
study is considered fibrosis prone, whereas other strains
(i.e., Balb/c) are resistant. Once other strains of p53-defi-
cient mice are available, it will be important to determine
whether or not p53’s ability to inhibit apoptosis in the lung
is mouse strain dependent.
An alternative interpretation of our results is that the
TUNEL method detects DNA damage due to direct bleo-
mycin-induced strand scission, and that the elevated
Figure 7. (A) iNOS is required for bleomycin-induced p53 activation in vivo. Wild-type and NOS-22/2 mice were exposed to bleomycin via in-
tratracheal instillation. After 2 h, alveolar macrophages were isolated by lavage, and nuclear p53 localization was analyzed by confocal microscopy. Note
strong nuclear p53 localization in cells from the iNOS1/1 animals that is absent from the iNOS2/2 cells. Arrows indicate treated iNOS2/2 macrophages
exhibiting apoptotic morphological changes. (B) TUNEL staining for apoptosis in situ. Animals were exposed to vehicle or 50 U/kg bleomycin for 5 h,
and apoptosis was analyzed by TUNEL staining. Original magnification: 320. (C) Localization of apoptotic cells in situ. TUNEL-stained slides from un-
treated or bleomycin-treated lungs were analyzed for distribution of apoptotic cells by LSC. Results are representative of three independent experiments.
(D) Quantification of apoptosis in situ. Apoptotic cells were counted in whole lung sections by LSC. Results are expressed as mean values 6 SEM from
sections obtained from three independent animals. A statistically significant difference (P 5 0.005) between wild-type and iNOS2/2 lungs was observed.866 p53 Suppresses Apoptosis in the Lung
Figure 8. Bleomycin induces rapid
expression of NOS-2. (A) Represen-
tative immunofluorescence images of
NOS-2 in lung sections obtained 5 h
after treatment with vehicle (control)
or bleomycin. (B) LSC-mediated
quantification of iNOS-positive cells.
Whole lung sections were analyzed by LSC. Results are presented as the total
number of iNOS-expressing cells. (C) Comparison of iNOS levels on un-
treated and bleomycin-treated cells. The cells analyzed in (B) were subse-
quently analyzed for fluorescence intensity by LSC. Resulting histograms re-
veal identical per-cell levels of iNOS. Results are representative of three
independent experiments.
Figure 9. Increased bleomycin-induced inflammation in iNOS2/2 and p532/2 mice. Animals were treated with 2.5 U/kg bleomycin via intratracheal
administration. At the times indicated, animals were killed and inflammation was assessed by histological analysis after hematoxylin and eosin staining.
Note profound inflammatory infiltrate by 7 d in the iNOS- and p53-deficient lungs. Indistinguishable results were observed in each of two animals at
each time point.867 Davis et al.
ceivable that the lack of significant iNOS expression ren-
ders the human lung more fibrosis prone compared with
the mouse lung.
The observation that bleomycin exposure leads to
marked increases in inflammation in the iNOS2/2 and
p532/2 mice (Fig. 9) supports our hypothesis that p53 acts
as a suppressor of inflammation in the lung through its abil-
ity to inhibit apoptosis. However, as noted above, the
C57BL/6 mice are considered fibrosis prone, perhaps be-
cause they mount a strong Th1-type response (as opposed
to a Th2 response) when challenged with proinflammatory
stimuli or because their responses to DNA damage are
unique. It will be of more interest to determine whether or
not p53 protects the human lung from inflammatory in-
jury. Patients with Li-Fraumeni syndrome possess germline
defects in the p53 gene that lead to increased cancer sus-
ceptibility (47). To our knowledge, no study has investi-
gated the possible relationship between expression of mu-
tant p53 and propensity to develop pulmonary fibrosis, but
our data would predict that these patients would exhibit in-
creased susceptibility. In addition, it is possible that individ-
ual differences in T cell response patterns will play a signif-
icant role in disease susceptibility.
Although the effects of fibrogenic agents almost certainly
involve reactive oxygen species, the effects of antioxidants
on the development of pulmonary inflammation and fibrosis
appear complex. Our data indicate that NO acts in a stress
response pathway that counteracts bleomycin-induced cell
death at the earliest stages of the response. However, abun-
dant evidence is available indicating that chronic treatment
with thiol antioxidants can partially inhibit bleomycin-
induced lung injury (10, 48). It is clear that the tissue-dam-
aging effects of neutrophils and basophils involve generation
of superoxide and other reactive oxygen species. In addition,
antioxidants can also inhibit the transcription factor, nu-
clear factor kB, which plays a central role in the inflamma-
tory cytokine networks involving TNF-a and IL-1b (49).
It should be noted that some studies have shown that NAC
does not attenuate lung injury, and one report argued that
the antioxidant exacerbated inflammation (50). Inhibition
of apoptosis by oxidative stress has been linked to inhibition
of caspase activation in other model systems (51), and our
results suggest that oxidative stress is also involved in pro-
moting p53’s antiinflammatory effects in the lung. Direct
analysis of particular redox-sensitive pathways will be re-
quired to determine the relative importance of each of
these candidate mechanisms.
Our data support the emerging idea that early apoptosis
contributes to inflammatory lung injury (27, 52–54), but
precisely how it does so remains unclear. One attractive
hypothesis is that the death of resident alveolar macro-
phages leads to loss of the balance between immunosuppres-
sive and proinflammatory cell types within the lung. Al-
though both resident and inflammatory macrophages can
ingest apoptotic debris, the former never leave the tissue
and are cleared by neighboring cells, whereas the latter mi-
grate to draining lymph nodes (55), where they may pro-
mote antigen presentation and T cell activation. In fact,
terminally differentiated macrophages can directly suppress
TUNEL levels observed in the p532/2 animals are due to
the absence of a p53-mediated mechanism that can repair
this damage. This explanation was offered by another
group who reported very similar increases in TUNEL-pos-
itive cells in p532/2 animals exposed to bleomycin in vivo
(39). Although we considered this possibility very seriously,
we have discounted it for several reasons. First, the pattern
of DNA fragmentation induced by bleomycin was charac-
teristic of apoptosis (Fig. 1 B) and not characteristic of the
direct (random) effects of bleomycin on DNA (40, 41).
This DNA fragmentation also took much longer to de-
velop (between 1 and 2 h) than the kinetics of direct strand
scission (essentially complete in minutes; reference 40).
Second, the bleomycin-induced DNA fragmentation we
measured in all of our assays was completely suppressed by
zVADfmk (Fig. 1 C), indicating that it occurs via a caspase-
dependent mechanism. Finally, recent work by Wyllie and
colleagues (42–44) has shown that DNA damage induced
by ionizing radiation is repaired equally well in p531/1 and
p532/2 cells. The emergence of mutation-bearing cells in
the p532/2 background is linked more closely to the inabil-
ity of the cells to engage the apoptotic pathway than to de-
fects in DNA repair, and apoptosis occurs well after all of
the initial DNA damage has been repaired.
Comparison of p53 localization after exposure of alveo-
lar macrophages to bleomycin in vitro and in vivo demon-
strated that p53 activation was strictly dependent on fac-
tor(s) within the lung microenvironment. Our subsequent
experiments established a central role for reactive oxygen
species, and in particular NO, in this response. Initially, we
found that the thiol antioxidant, NAC, blocked p53 activa-
tion, a result that is consistent with a role for reactive oxy-
gen species in the response. A search for candidate media-
tor(s) demonstrated that NO donors can substitute for the
lung microenvironment to promote p53 activation in vitro.
Our studies with macrophages isolated from NOS-22/2
mice confirmed that iNOS is required for bleomycin-
mediated p53 activation in vivo. A role for NO in p53 ac-
tivation is well established (9), although the biochemical
mechanism(s) involved remain unclear. One previous study
presented evidence that NO promotes stabilization of p53
via inhibition of proteasome-mediated degradation of the
protein (25), and another recent study suggests that NO
can directly nitrosylate tyrosine residues in p53 (45). The
data demonstrating bleomycin-induced nuclear p53 relo-
calization strongly suggest that protein stabilization alone
does not explain the effects of NO on p53 function. Nota-
bly, proteasome inhibitors, which block p53 degradation in
most cell types, do not promote p53 phosphorylation or
nuclear relocalization by themselves (our unpublished ob-
servations).
One potential caveat of our experiments is that NOS-2
has been difficult to demonstrate in human macrophages
(46). In this sense, the mouse alveolar macrophage may not
serve as a perfect model for the corresponding human cells.
However, it is possible that in response to lung injury, hu-
man alveolar macrophages (or some other resident cell
type) generate NO via the action of a different NOS
isozyme(s) (cNOS or eNOS). Alternatively, it is also con-868 p53 Suppresses Apoptosis in the Lung
T cell activation (56) by competing with resident dendritic
cells for engulfment of the apoptotic debris that serves as
the source of antigens for presentation (15). Furthermore,
resident tissue macrophages play a critical role in clearing
neutrophils (57). Neurophils have an extremely short half-
life, and recent work by Haslett and colleagues (58) has
shown that levels of neutrophil influx correlate well with
the extent of pulmonary fibrosis in several models of the
disease (58). Additional effort is required to determine pre-
cisely how apoptotic cell clearance regulates tolerance to
self-antigens within the lung.
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